$4.22-0.19 (-4.29%)
Zepp Health Corporation operates as a smart wearable and health technology company worldwide.
Zepp Health Corporation in the Technology sector is trading at $4.22 with a market capitalization of $100M. Wall Street consensus targets $56.28 (1 analysts), implying a +1233.6% move over the next 12 months. The stock is currently near its 52-week low of $2.25, remaining 84.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $85.17M↑ | $75.79M↑ | $59.41M↑ | $38.54M↓ | $59.54M |
| Gross Profit | $34.41M↑ | $28.92M↑ | $21.49M↑ | $14.36M↓ | $21.93M |
| Operating Income | -$3.87M↓ | -$884,000↑ | -$6.10M↑ | -$18.38M↓ | -$8.94M |
| Net Income | -$10.97M↓ | -$1.62M↑ | -$7.74M↑ | -$19.74M↑ | -$36.88M |
Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp A...
Zepp Health Corp (ZEPP) reports a 33.8% increase in revenue and narrows operating losses, driven by successful product launches and strategic partnerships.
Zepp Health (NYSE:ZEPP) reported a stronger start to 2026, with management pointing to new Amazfit product launches, a higher-end product mix and expanding positioning in hybrid training as the main drivers of first-quarter growth. On the company’s earnings call, Founder and Chief Executive Officer
Zepp Health Corporation ( NYSE:ZEPP ) is possibly approaching a major achievement in its business, so we would like to...
Zepp Health Corp (ZEPP) reports a 43% year-over-year revenue increase and unveils new product launches and strategic partnerships despite ongoing challenges.
Zepp Health (NYSE:ZEPP) executives highlighted accelerating growth, expanding margins, and a continued shift toward higher-priced products during the company’s fourth quarter and full-year 2025 earnings call, while outlining expectations for another year of revenue expansion in early 2026. Manageme